)
Sutro Biopharma (STRO) investor relations material
Sutro Biopharma Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Pipeline strategy and platform
Since the pivot last March, the development plan accelerated from three clinical programs in three years to three in two years; two are in clinic, with a third expected to enter early next year.
Tissue Factor and integrin beta-6 were selected as complex targets to establish single-payload ADC performance and support later dual-payload development.
Cell-free engineering, tumor-cleavable β-glucuronidase linkers and non-natural amino acids enable component optimization, site-specific conjugation and tunable payload ratios.
The linker strategy is intended to reduce premature payload release and cytopenias; the platform can also support high drug-to-antibody ratios, including DAR16 without compromising PK.
STRO-004
Early clinical activity was reported across pancreatic, head and neck, and lung cancers in heavily pretreated U.S. patients; the August cohort included irinotecan exposure in all PDAC and CRC patients, with some exposed more than once.
Safety was described as manageable, with mostly grade 1–2 AEs, limited hematologic and target-related toxicity, and low discontinuation; mitigation for stomatitis and ocular AEs appeared manageable.
PK included a seven-day half-life, 98% DAR8 configuration and no observed free-payload spike; management expects this profile to reduce circulating free payload and related cytopenias.
A fuller efficacy update is planned for H1 2027, alongside dose expansion in an earlier-line population; dose escalation backfill cohorts target 10–12 patients per dose and indication.
Current dose escalation spans multiple doses and tumor types; management aims to build a more informative patient sample at optimized doses and may begin regulatory discussions as data mature.
STRO-006
STRO-006 targets integrin beta-6 and uses the same linker-payload design as STRO-004; broad expression across lung and head and neck cancers supports a basket approach.
Initial dosing is planned at 1.5 mg/kg, with management expecting to reach active dose levels sooner; initial data are guided for H2 2027.
After reaching active doses, the study may narrow its tumor basket to prioritize lung and head and neck cancers and maximize early activity signals.
- Three ADC catalysts in 2027, with STRO-004 activity and runway into H1 2028.STRO
Corporate presentation - Pipeline advanced as costs narrowed losses, with $142.2M cash and further financing needed.STRO
Q3 2026 - Three clinical programs and multiple data catalysts are planned for 2027.STRO
Stifel 2026 Healthcare Conference 2026 - STRO-004 clinical activity anchors a growing single- and dual-payload ADC pipeline.STRO
Investor presentation - Accelerated clinical progress and dual payload innovation drive promising oncology pipeline.STRO
H.C. Wainwright 28th Annual Global Investment Conference - Advancing next-gen ADCs with strong clinical progress and a robust, well-funded pipeline.STRO
Corporate presentation - Q2 2026 revenue was $9.8M, net loss $38.5M, and strong pipeline and cash position highlighted.STRO
Q2 2026 - Directors elected, auditor ratified, and executive pay approved; clinical goals accelerated.STRO
AGM 2026 - ADC pipeline advances with clinical, preclinical, and partnership milestones set for 2026.STRO
R&D Day 2025
)
)
)
)
)
)
)
)